根据白花油此前发布的截至2025年6月30日止6个月中期业绩，该集团取得收入9473.4万港元，同比减少 28.5%；报告溢利3974.3万港元，同比减少16.2%；基础经常性溢利4529.4万港元，同比减少26.6%；报 告溢利每股盈利12.8港仙，拟派发中期股息每股3港仙及特别中期股息每股5港仙。 香港联交所最新资料显示，1月2日，白花油(00239)股东将股票由USB Securities Hong Kong Limited转入 香港上海汇丰银行，转仓市值3823.61万港元，占比5.18%。 ...

近日刚刚完成证券简称变更、正积极推进H股上市的福瑞医科（300049）12月31日晚间发布整改报告。 2025年12月31日晚，福瑞医科发布整改报告称，公司收到内蒙监管局于2025年12月10日出具的《关于对 内蒙古福瑞医疗科技股份有限公司采取责令改正措施并对相关责任人员采取出具警示函措施的决定》 （以下简称"《决定书》"），要求公司对《决定书》中指出的境外子公司管理内部控制不完善、公司收 入核算不规范等问题进行整改。 《决定书》显示，福瑞医科对境外子公司管理内部控制不完善。福瑞医科未建立母公司对重要境外子公 司的内部控制及风险管理制度，公司内设部门未对境外子公司开展检查和监督。 对此，福瑞医科表示，公司已制定《福瑞股份：境外子公司管理办法》，完善母公司对重要境外子公司 的内部控制及风险管理制度框架，进一步明确了重要境外子公司在战略规划、重大决策、合规经营等方 面的管理要求。 福瑞医科还表示，公司审计部已对重要境外子公司发出审计通知书，同时委托专业机构协助公司对重要 境外子公司开展专项内部审计，保障内审工作的专业性和执行效果。福瑞医科将严格依据《福瑞股份： 境外子公司管理办法》，落实对重要境外子公司的常态化检 ...

（央视财经《天下财经》）当地时间22日，美国马里兰州一个陪审团裁定，美国强生公司需向因使用其 婴儿爽身粉产品而罹患癌症的一名女子，支付超过15亿美元赔偿。 23日，强生公司表示将立即启动上诉程序。多年来，针对强生婴儿爽身粉及其他滑石粉产品含石棉致癌 的诉讼几乎从未停止过。美国媒体称，此次判决是强生公司相关诉讼持续15年来，单一原告获赔金额最 高的判决。 转载请注明央视财经 编辑：令文芳 22日，美国马里兰州巴尔的摩市巡回法院的一个陪审团裁定，强生公司需向马里兰州一名女子支付约 15.6亿美元、约合人民币110亿元赔偿。这名女子指控强生公司的婴儿爽身粉产品含有石棉，导致她患 上一种癌症——间皮瘤。陪审团认为，强生公司对未能警告原告其婴儿爽身粉含有石棉负有责任。 目前，强生面临的相关诉讼超6.7万起。研究显示，爽身粉原料滑石粉的矿藏常常位于含石棉矿藏附 近，滑石粉被开采时可能沾染石棉。强生公司否认所生产的爽身粉含石棉，称已做过广泛测试，确保产 品没有受到石棉污染。2020年，强生宣布，在美国和加拿大停止销售含滑石粉的婴儿爽身粉，停售理由 是"致癌"风波导致产品销量下滑，之后将以玉米淀粉为主原料的产品来替代。202 ...

格隆汇12月11日｜中邮证券研报指出，上海医药商业板块稳健增长，Q3减值影响利润，看好创新业务 驱动成长。公司医药商业业务继续保持增长韧性，优势区域增长态势强劲，器械大健康业务表现亮眼， 新零售战略调整成效显现，CSO业务规模再创新高，创新药产品结构持续优化，供应链服务面向专业化 与价值链高端延伸。2025Q1-3公司创新药业务实现销售收入407亿元，同比增长超过25%；进口总代业 务实现销售收入276亿元，同比增长超过14%；器械大健康业务实现销售收入339.88亿元，同比增长超 过4%。截至2025年9月30日，公司提交临床试验申请获得受理及进入后续临床试验阶段的新药管线共计 57项，包括创新药管线45项。维持"买入"评级。 ...

在一份官方备忘录提及10例儿童接种后死亡案例后，FDA正调查"多个年龄组"的死亡事件；此前研究已 表明严重不良反应极为罕见。 责任编辑：张俊 SF065 在一份官方备忘录提及10例儿童接种后死亡案例后，FDA正调查"多个年龄组"的死亡事件；此前研究已 表明严重不良反应极为罕见。 责任编辑：张俊 SF065 ...

在全球医疗技术革新与健康需求升级的浪潮中，百洋医药（301015.SZ）锚定精准放疗赛道，构建起"全 球技术引进培育、中国制造供应全球、放疗中心服务创新、临床科研持续验证"的全链条大放疗战略体 系。 2025年12月5日至9日，百洋医药围绕ZAP-X火星舟放射外科机器人（以下简称"ZAP-X"），接连实现全 球制造基地投产、临床研究启动、放疗中心落地等重要进展。随着ZAP-X在中国的临床推广迈入规模 化、规范化新阶段，百洋医药的大放疗战略也正步入成果兑现的收获期。 全球技术引进培育：核心技术填补临床空白 我国每年脑转移瘤新发病例高达150万，治疗难度极大、患者生存期短，已成为临床诊疗中亟待突破的 重大挑战。而传统手术、化疗及常规放疗均存在治疗局限：传统手术难以避免神经功能损伤，大部分化 疗药物难以穿透血脑屏障，常规放疗对肿瘤周边健康脑组织的保护力度不够。基于对这一严峻临床形势 的深刻洞察，百洋医药于2024年11月战略投资美国硅谷的ZAP Surgical，全面负责ZAP-X在中国的商业 化运营，并同步启动全球规模化生产的布局。 ZAP-X作为专为颅脑精准放疗而设计的革命性设备，凭借独创的双回旋球形结构，可实 ...

Group 1 - The core point of the announcement is that shareholder Mr. Ruan Hongxian has repaid a stock pledge financing agreement with Huatai Securities ahead of schedule, releasing 6.2 million shares from pledge [1][2] - As of the announcement date, Mr. Ruan has a total of 148.61529 million shares that remain unpledged, indicating a significant buffer against potential margin calls [3] - The company will continue to monitor Mr. Ruan's stock pledge situation and will announce any changes promptly [3] Group 2 - The company has approved the use of up to RMB 2.5 billion of temporarily idle self-owned funds for cash management, which includes investments in fixed-income products and time deposits [7] - The company has begun to recover funds from cash management products that have reached maturity, indicating active management of its idle funds [7] - Relevant documents related to the cash management activities have been prepared for review [8]

Core Insights - The average approval time for imported medical devices and drugs in the Hainan Boao Lecheng International Medical Tourism Pilot Zone has been reduced to 1.6 days, facilitating faster access to international innovations for patients in China [1][2] - The Lecheng Pilot Zone has successfully introduced 523 types of international innovative medical devices and drugs, benefiting over 180,000 patients, and aims to further enhance its medical technology and drug importation efforts [2][3] Group 1 - The first global hormone replacement therapy drug for hypoparathyroidism, parathyroid hormone replacement therapy, has been successfully used by a patient in Hainan, despite not being officially launched in mainland China [2] - The Lecheng Pilot Zone's unique policies, including "licensed medical devices" and "real-world research," have enabled a significant reduction in the approval process for new medical products [2][3] - The introduction of a "zero tariff" policy for imported medical devices and drugs has further streamlined the process, reducing the average approval time from 5 working days to 1 working day [2] Group 2 - The ongoing China International Import Expo has attracted over 30 renowned domestic and international pharmaceutical and medical device companies, indicating strong interest in the Lecheng Pilot Zone [3] - The Lecheng Pilot Zone has established deep cooperative relationships with over 180 pharmaceutical and medical device companies from 20 countries and regions, including many of the top 30 global firms [3] - The management of the Lecheng Pilot Zone plans to refine the tax-exempt catalog for medical devices and drugs, aiming to create a world-class international medical tourism destination and a medical innovation platform [3]

Core Viewpoint - Aipeng Medical and Cube Pharmaceutical signed a strategic cooperation framework agreement to establish a joint innovation center focusing on rapid response mechanisms for clinical needs, technology research and development, and achievement transformation [1] Group 1: Strategic Cooperation - The partnership aims to conduct joint research on AI, brain-computer interfaces, and drug efficacy evaluation [1] - The collaboration will promote coordinated clinical research between medical devices and pharmaceuticals [1] Group 2: Academic and Social Engagement - Both companies will collaborate with academic institutions and industry associations to facilitate scientific exchanges and public awareness activities [1] - The initiative aims to enhance standardized diagnosis and treatment of ADHD and improve social recognition [1]

Group 1 - The core point of the news is that Furuya Co., Ltd. experienced a 5.01% drop in stock price, closing at 70.75 yuan per share, with a trading volume of 5.25 billion yuan and a turnover rate of 3.13%, resulting in a total market capitalization of 187.47 billion yuan [1] - Furuya Co., Ltd. is primarily engaged in the production and sales of drugs in the liver disease sector, as well as the research and sales of medical instruments and medical services. The revenue composition is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1] Group 2 - Among the top ten circulating shareholders of Furuya Co., Ltd., a fund under Ruiyuan Fund holds a significant position. Ruiyuan Growth Value Mixed A (007119) reduced its holdings by 639,300 shares in the third quarter, now holding 4.9273 million shares, which accounts for 2.11% of the circulating shares. The estimated floating loss today is approximately 18.3787 million yuan [2] - Ruiyuan Growth Value Mixed A (007119) was established on March 26, 2019, with a current scale of 21.387 billion yuan. Year-to-date returns are 68.09%, ranking 478 out of 8,152 in its category; the one-year return is 64.4%, ranking 546 out of 8,038; and since inception, the return is 100.9% [2]